Hjem › Crohns sykdom › Rhode Island
Kliniske studier for Crohns sykdom i Rhode Island
12 studier for Crohns sykdom søker deltakere på steder i Rhode Island.
Byer i Rhode Island
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University Gastroenterology - Providence - West River Street ( Site 5057), Providence
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- University Gastroenterology - Providence - Staniford Street /ID# 280919, Providence
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- University Gastroenterology, Providence
RekruttererFase 4
Alder 18 til 80 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology, Providence
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology Providence, Providence
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- University Gastroenterology, Providence
RekruttererFase 3
Alder 18 til 70 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology-Site Number: 8400103, Providence
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology - GI Alliance-Site Number: 8400103, Providence
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184944A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University Gastroenterology, Providence
RekruttererFase 4
Alder 18 til 70 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Gastroenterology Associates, Providence
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT05230173Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Rhode Island Hospital, Providence
RekruttererFase 4
Alder 6 til 17 · Alle kjønn · Oppdatert 27. mai 2026 · NCT05781152A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Providence
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 12. mar. 2026 · NCT07113522Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.